
miRecule
Mirecule, Inc.: A Maryland-based biotech firm specializing in RNA therapeutics for cancer and muscular dystrophy.

Mirecule, Inc.: A Maryland-based biotech firm specializing in RNA therapeutics for cancer and muscular dystrophy.
Founded in Maryland, miRecule is a biotechnology company focused on developing RNA therapies for cancer and muscular dystrophy. The company's core mission is to harness genomic patient data to create highly tailored therapeutics, aiming to alleviate the debilitating symptoms of these disorders. miRecule's proprietary DREAmiR™ platform leverages genomic and outcome data to design precise RNA-based treatments, offering a personalized approach to medicine.
Notable figures associated with miRecule include a team of experienced biotech professionals and researchers dedicated to advancing RNA therapeutic technologies. The company has attracted significant interest from investors in the biotechnology sector, contributing to its rapid development and innovation. miRecule's key achievements include the successful application of their DREAmiR™ platform in preclinical studies, demonstrating potential efficacy in treating head and neck cancer as well as muscular dystrophy. The overall impact of miRecule lies in its pioneering approach to personalized RNA therapy, promising improved outcomes for patients with severe genetic disorders.
Companies similar to miRecule include ReviR Therapeutics, Curamir Therapeutics, Inspirna and Rnaimmune.
miRecule was founded in 2016.
miRecule's headquarters is located in Gaithersburg, MD, US.
miRecule's most recent funding round was for $5.7M (USD) in May 2021.
As of May 28, 2021, miRecule has disclosed funding of $7.2M (USD). Undisclosed round amounts are excluded.
miRecule has 11 employees as of Feb 5, 2024.

Rnaimmune
rnaimmune.com